Christian Lood1, Grant C Hughes1. 1. Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, USA.
Abstract
Objective: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with ANCAs targeting neutrophil elastase (NE), neutropenia and vasculitic/thrombotic skin purpura. The mechanisms of cocaine/levamisole-associated autoimmunity (CLAA) are unknown. The aim of this study was to assess the ability of cocaine and levamisole to induce the release of neutrophil extracellular traps (NETs), a potential source of autoantigen and tissue injury. Methods: We performed quantitative and qualitative assessment of NET formation in neutrophils from healthy donors exposed to either drug in vitro . In addition, IgG from sera of individuals with CLAA (CLAA-IgG) was assessed for its ability to enhance formation of, and to bind to, drug-induced NETs. Results: Both cocaine and levamisole could induce formation of NETs enriched in NE and, potentially, inflammatory mitochondrial DNA. Both drugs could also augment simultaneous release of B cell-activating factor belonging to the TNF family (BAFF). CLAA-IgG, but not IgG from healthy individuals, could potentiate drug-induced NETosis. Furthermore, CLAA-IgG, but not ANCA + control IgG, bound to drug-induced NETs in a pattern consistent with NE targeting. Conclusion: Both cocaine and levamisole may contribute to the development of ANCAs by inducing release of potentially inflammatory NETs in association with NE autoantigen and BAFF. Enhancement of drug-induced NET release by CLAA-IgG provides a potential mechanism linking vasculitis/pupuric skin disease to acute drug exposure in patients with CLAA. Further study of this under-recognized form of autoimmunity will be likely to provide mechanistic insight into ANCA-associated vasculitis and other diseases associated with NETosis.
Objective: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with ANCAs targeting neutrophil elastase (NE), neutropenia and vasculitic/thrombotic skin purpura. The mechanisms of cocaine/levamisole-associated autoimmunity (CLAA) are unknown. The aim of this study was to assess the ability of cocaine and levamisole to induce the release of neutrophil extracellular traps (NETs), a potential source of autoantigen and tissue injury. Methods: We performed quantitative and qualitative assessment of NET formation in neutrophils from healthy donors exposed to either drug in vitro . In addition, IgG from sera of individuals with CLAA (CLAA-IgG) was assessed for its ability to enhance formation of, and to bind to, drug-induced NETs. Results: Both cocaine and levamisole could induce formation of NETs enriched in NE and, potentially, inflammatory mitochondrial DNA. Both drugs could also augment simultaneous release of B cell-activating factor belonging to the TNF family (BAFF). CLAA-IgG, but not IgG from healthy individuals, could potentiate drug-induced NETosis. Furthermore, CLAA-IgG, but not ANCA + control IgG, bound to drug-induced NETs in a pattern consistent with NE targeting. Conclusion: Both cocaine and levamisole may contribute to the development of ANCAs by inducing release of potentially inflammatory NETs in association with NE autoantigen and BAFF. Enhancement of drug-induced NET release by CLAA-IgG provides a potential mechanism linking vasculitis/pupuric skin disease to acute drug exposure in patients with CLAA. Further study of this under-recognized form of autoimmunity will be likely to provide mechanistic insight into ANCA-associated vasculitis and other diseases associated with NETosis.
Authors: Jonatan Leffler; Myriam Martin; Birgitta Gullstrand; Helena Tydén; Christian Lood; Lennart Truedsson; Anders A Bengtsson; Anna M Blom Journal: J Immunol Date: 2012-02-17 Impact factor: 5.422
Authors: Anthony J O'Donoghue; Ye Jin; Giselle M Knudsen; Natascha C Perera; Dieter E Jenne; John E Murphy; Charles S Craik; Terry W Hermiston Journal: PLoS One Date: 2013-09-20 Impact factor: 3.240
Authors: Carmelo Carmona-Rivera; Monica M Purmalek; Erica Moore; Meryl Waldman; Peter J Walter; H Martin Garraffo; Karran A Phillips; Kenzie L Preston; Jonathan Graf; Mariana J Kaplan; Peter C Grayson Journal: JCI Insight Date: 2017-02-09
Authors: Mary Bach; Jeonghun Moon; Richard Moore; Tiffany Pan; J Lee Nelson; Christian Lood Journal: Arthritis Rheumatol Date: 2019-12-03 Impact factor: 10.995
Authors: Jana Blazkova; Sarthak Gupta; Yudong Liu; Brice Gaudilliere; Edward A Ganio; Christopher R Bolen; Ron Saar-Dover; Gabriela K Fragiadakis; Martin S Angst; Sarfaraz Hasni; Nima Aghaeepour; David Stevenson; Nicole Baldwin; Esperanza Anguiano; Damien Chaussabel; Matthew C Altman; Mariana J Kaplan; Mark M Davis; David Furman Journal: J Immunol Date: 2017-02-08 Impact factor: 5.422
Authors: Stanley Moore; Hsin-Hsuan Juo; Christoffer T Nielsen; Helena Tyden; Anders A Bengtsson; Christian Lood Journal: J Rheumatol Date: 2019-12-15 Impact factor: 4.666
Authors: Tamara Hoppenbrouwers; Anouchska S A Autar; Andi R Sultan; Tsion E Abraham; Wiggert A van Cappellen; Adriaan B Houtsmuller; Willem J B van Wamel; Heleen M M van Beusekom; Johan W van Neck; Moniek P M de Maat Journal: PLoS One Date: 2017-05-09 Impact factor: 3.240